Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Skye Bioscience, Inc. Director's Dealing 2020

Aug 11, 2020

34097_dirs_2020-08-11_cebb3398-a19c-49c4-b4bd-2109eabe5eb2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emerald Bioscience, Inc. (EMBI)
CIK: 0001516551
Period of Report: 2020-08-07-05:00

Reporting Person: KIM DENNIS D (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-08-07-05:00 Employee Stock Option (Right to Buy) $0.045 A 4000000 Acquired 2030-08-07-05:00 Common Stock (4000000) Direct

Footnotes

F1: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four years.